OPKO Health Target of Unusually Large Options Trading (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders bought 5,038 call options on the stock. This represents an increase of approximately 101% compared to the typical volume of 2,501 call options.

OPKO Health Price Performance

OPK stock remained flat at $1.42 on Friday. The company had a trading volume of 2,160,919 shares, compared to its average volume of 3,926,301. OPKO Health has a 52-week low of $1.15 and a 52-week high of $2.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company has a fifty day moving average of $1.67 and a two-hundred day moving average of $1.57. The company has a market cap of $953.60 million, a price-to-earnings ratio of -7.47 and a beta of 1.78.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. On average, equities research analysts predict that OPKO Health will post -0.25 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.36 per share, with a total value of $170,000.00. Following the completion of the transaction, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. This represents a 0.06 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 814,971 shares of company stock worth $1,308,192 over the last 90 days. Corporate insiders own 49.69% of the company's stock.

Institutional Trading of OPKO Health

Institutional investors have recently bought and sold shares of the company. FMR LLC boosted its position in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after buying an additional 11,089 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of OPKO Health in the first quarter valued at approximately $43,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 12,417 shares in the last quarter. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health during the 3rd quarter worth approximately $45,000. Finally, Cibc World Markets Corp purchased a new stake in OPKO Health in the 4th quarter valued at approximately $45,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on OPK. StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. Finally, Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.